OnCore licenses Cytos' VLP platform for HBV

HBV play OnCore Biopharma Inc. (Doylestown, Pa.) obtained an exclusive license to use the virus-like particle (VLP) platform from Cytos Biotechnology AG (SIX:CYTN) to develop therapies for HBV and

Read the full 296 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE